During the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the AML Hub spoke to Rémy Duléry, Hôpital Saint-Antoine, Paris, FR, about sequential therapy in patients with relapsed/refractory acute myeloid leukemia (AML).

For patients with AML in primary treatment failure, the chance of a complete remission is only 10–20%, and overall survival at 1 year is less than 10%, clearly demonstrating the great need for improved management options for this group. To discuss this further, we asked, How should sequential therapy be performed in patients with AML?

свернуть